Celera genome licensing terms spark concerns over 'monopoly'

Article Abstract:

There are concerns that Celera Genomics Corporation may obtain a monopoly over human genome data. Previously, Celera president Craig Venter, promised under oath that data from the human genome would be made available to the public domain, but sequence data will now be released on the company's own web site, or provided to researchers on DVD discs. Many researchers believe that such a license arrangement would preclude the free use of the data.

Information services, Licensing agreements

---

Celera turns to public genome data to speed up endgame...

Article Abstract:

Celera Genomics Corp has sequenced 81% of the human genome, and has linked this with publicly available data to cover 90% of the genome. The company plans to combine lower-quality sequence with data from the Human Genome Project, and will therefore sequence the human genome fewer times than previously planned. It seems to have abandoned its plan to 'shotgun sequence' the entire human genome alone by sequencing millions of DNA fragments without knowing where they fit in the genome.

Management, Human Genome Project, Celera Genomics Group

---

Draft data leave geneticists with a mountain still to climb

Article Abstract:

Issues are presented concerning the large amount of work still to be completed by human geneticists working on the draft sequence of the human genome. About 20% of the genome sequence had been mapped by June 00.

Similar abstracts:

• Abstracts: UK government backs change in law over stem-cell research ... but Germany remains unmoved. Europe lifts patent embargo on transgenic plants and animals...
• Abstracts: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I-kappa-B kinase. NAK is an IkB kinase-activating kinase

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.